Aldosterone activates the epithelial sodium channel (ENaC) in principal cells of the collecting duct to regulate salt excretion, extracellular volume, and BP. Seminal studies by Hostetter and colleagues demonstrated that aldosterone also contributes to glomerular sclerosis in a remnant kidney model. Treatment of rats with aldosterone and salt induces an inflammatory response, characterized by perivascular leukocyte infiltration and increased expression of proinflammatory and profibrotic genes through a mineralocorticoid receptor (MR)-dependent mechanism. Not surprising, MR activation by aldosterone stimulates the expression of proinflammatory and profibrotic genes through a MR-dependent mechanism in cultured vascular cells, mesangial cells, podocytes, and fibroblasts. In this issue of JASN, however, Leroy et al. report that aldosterone also activates the canonical NF-κB pathway and proinflammatory genes in cultured principal cells, the site of MR-mediated sodium reabsorption and potassium excretion. Whereas in mesangial cells and vascular smooth muscle cells, aldosterone activates p38 and extracellular signal–regulated kinases 1 and 2, aldosterone stimulates NF-κB in principal cells through an MR-dependent increase in serum and glucocorticoid-induced kinase 1 (SGK1) expression but not through extracellular signal–regulated kinase or p38.

Leroy et al. also observed in vivo in rats that dietary salt restriction, associated with increased circulating concentrations of aldosterone, increases MR-dependent expression of mRNA encoding NF-κB and SGK1 in the cortical collecting duct. Whether activation of the glucocorticoid receptor in vivo would dampen the proinflammatory effects of MR activation under pathophysiologic conditions in which both aldosterone and cortisol (or corticosterone) are elevated, as glucocorticoid receptor activation did in vitro, was not specifically addressed.

What is the physiologic relevance of this convergence of salt reabsorption and inflammatory stimulation in the principal cell? It is possible that, during low salt intake, increased inflammation puts a break on sodium reabsorption. The same group previously reported that prolonged activation of NF-κB by LPS decreases expression of SGK1 and activity of the ENaC-α subunit, as well as basal, glucocorticoid, and mineralocorticoid-stimulated sodium transport in cultured principal cells. Bens et al. also reported that LPS reduced amiloride-sensitive ion fluxes in cultured cortical collecting duct cells. In addition, increased expression of the NF-κB target gene plasminogen activator inhibitor 1 (PAI-1) during low salt intake could decrease activation of ENaC by decreasing plasmin-mediated proteolytic cleavage of its γ subunit.

Although Leroy et al. found that low salt intake increases MR-dependent activation of NF-κB in the collecting duct, it is well established that high salt intake enables the proinflammatory and profibrotic effects of aldosterone in the kidney in whole-animal studies. High salt intake paradoxically activates renal MR in obese hypertensive rats, resulting in increased translocation of the MR to the nucleus, increased expression of SGK1, and increased NF-κB activity. Although the cell specificity of this effect is not known, MR antagonism decreases renal NF-κB expression and glomerular podocyte injury in parallel during high salt intake. Taken together with the observation that low salt intake increases MR-dependent inflammation in the cortical collecting duct, it is possible that salt intake modulates the site and proinflammatory effect of aldosterone in the kidney. Increased oxidant stress also contributes to salt-induced activation of renal MR, in that the antioxidant tempol prevents the effect. Likewise, aldosterone increases PAI-1 expression in mesangial cells in part through increased oxidative stress and TGF-β. It would be interesting to know whether increased oxidative stress contributes to the MR-dependent activation of NF-κB in the cortical collecting duct during low salt intake.

Aldosterone or MR activation causes both tubulointerstitial fibrosis and glomerulosclerosis in animal models. Thus, the MR antagonists spironolactone and eplerenone decrease interstitial inflammation and glomerular injury in rats with radia
tion injury, unilateral ureteral obstruction, diabetes, and aldosterone infusion.\textsuperscript{3,12} MR inhibition even reverses preexisting glomerulosclerosis in a five-sixths nephrectomy model.\textsuperscript{13} The extent to which increased expression of NF-\text{k}B–targeted genes contribute to aldosterone-induced renal injury may be de-
duced from studies in genetically deficient mice. Obese (db/db) mice genetically deficient in MCP-1 are protected against proteinuria, inflammation, and glomerulosclerosis\textsuperscript{14,15}; whether MCP-1 deficiency protects against aldosterone-induced renal injury per se has not been reported, but obesity is associated with increased circulating aldosterone concentrations. PAI-1–deficient mice are also protected from aldosterone/salt-induced glomerulosclerosis\textsuperscript{13}; in contrast, PAI-1 deficiency does not protect against interstitial inflammation in response to aldosterone and salt treatment.

What implications do these studies have for the treatment of patients? Activation of the renin-angiotensin-aldosterone system increases whereas MR antagonism decreases circulating IL-6 and PAI-1 concentrations in humans.\textsuperscript{16} Whether MR activation decreases renal cytokine or PAI-1 expression in hu-
man disease requires further study.

Our understanding of the pathophysiologic role of aldosterone has progressed during the past 15 yr, and the clinical use of MR antagonists has seen resurgence. We often contrast the proinflammatory/profibrotic effects of aldosterone in nonepi-
thelial cells to the classic physiologic role of aldosterone in renal sodium transport. The studies of Leroy et al. suggest that, in the kidney, these two effects are more inti-
mately linked than previously appreciated.

DISCLOSURES
None.

REFERENCES

7. Terada Y, Kuwana H, Kobayashi T, Okado T, Suzuki N, Yoshimoto T, Hirata Y, Sasaki S: Aldosterone-stimulated SGK1 activity mediates profi-
8. de Seigneux S, Leroy V, Ghzili H, Rousselot M, Nielsen S, Rossier BC, Martin PY, Feraille E: NF-\text{k}appaB inhibits sodium transport via down-
15. Ma J, Weisberg A, Griffin JP, Vaughan DE, Fogo AB, Brown NJ: Plasminogen activator inhibitor-1 deficiency protects against aldoste-
17. Takebayashi K, Matsumoto S, Aso Y, Inukai T: Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nep-
phropathy. \textit{J Clin Endocrinol Metab} 91: 2214–2217, 2006

See related article, “Aldosterone Activates NF-\text{k}B in the Colleting Duct,” on pages 131–144.

Unified Ultrasonographic Diagnostic Criteria for Polycystic Kidney Disease

Franck A. Belibi and Charles L. Edelstein

Division of Renal Diseases and Hypertension, University of Colorado Denver, Aurora, Colorado


Autosomal dominant polycystic kidney disease (ADPKD) is the most common life-threatening hereditary disease in the